Depression and anxiety are among the most common mental illnesses. Our group focuses on hard-to-treat cases of these conditions. Our interests include:
Monoamine Oxidase Inhibitors (MAOIs)
These medicines are the best treatment for many depressed patients but are rarely used due to potential dangerous interactions with certain foods. We helped develop a safe and effective transdermal preparation (skin patch) with minimal dietary interactions.
Refractory Depression and Residual Symptoms of Depression
We study new medicines for treatment resistant depression as well as adjunctive medicines for residual symptoms such as apathy or impaired concentration.
Reconsideration of Opioids as a Treatment for Depression
Opiates were the first antidepressants prescribed by physicians but were abandoned in the mid-twentieth century for safety reasons. Buprenorphine is a safer opioid with reduced potential for abuse. We were among the first to publish evidence of its effectiveness in treating depression that is unresponsive to conventional antidepressants.
In addition, we evaluate new medications for treating chronic anxiety and sleep difficulties.
The Clinical Psychopharmacology Research Program was founded in 1998.